Bisphosphonates and metastatic breast carcinoma

Cancer

Volumn 97, Issue 3 SUPPL., 2003, Pages 848-853

  Lipton, Allan ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Bisphosphonates; Bone metastasis; Breast carcinoma; Clodronate; Pamidronate; Zoledronic acid

Indexed keywords

AMGN 0007; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; IBANDRONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PARATHYROID HORMONE RELATED PROTEIN; PLACEBO; PROTEIN TYROSINE KINASE; RISEDRONIC ACID; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

BONE DEVELOPMENT; BONE METASTASIS; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HYPERCALCEMIA; MAJOR CLINICAL STUDY; MORBIDITY; MULTICENTER STUDY; OSTEOLYSIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; VERTEBRA FRACTURE;

EID: 0037301970     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11123     Document Type: Conference Paper

References (36)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin. 1999;49:8-31.
2. Coleman RE. Skeletal complications of malignancy. Cancer. 1997;30:1588-1594.
3. Hortobagyi GN. Bone metastases in breast cancer patients. Semin Oncol. 1991;18(Suppl 5):11-15.
4. Miller F, Whitehill R. Carcinoma of the breast metastatic to the skeleton. Clin Orthop. 1984;184:121-127.
5. Sherry MM, Greco FA, Johnson DH, Hainsworth JD. Metastatic breast cancer confined to the skeletal system. An indolent disease. Am J Med. 1986;81:381-386.
6. Yamashita K, Koyama H, Inaji H. Prognostic significance of bone metastasis from breast cancer. Clin Orthop. 1995;317: 89-94.
7. Fleisch H. Bisphosphonates: mechanism of action and clinical application. J Bone Miner Res. 1983;1:319-357.
8. Fleisch H. Bisphonates: a new class of drugs in disease of bone and calcium metabolism. Recent Results Cancer Res. 1989;116:1-28.
9. Paterson AHG, Powles TJ, Kanis TA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol. 1993;11:59-65.
10. Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C. Long-term prevention of skeletal complications of metastatic breast carcinoma and pamidronate. J Clin Oncol. 1998;16:2038-2044.
11. Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol. 1999;17:846-895.
12. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast cancer and osteolytic bone metastases: long-term follow-up of two randomized, placebo-controlled trials. Cancer. 2000;88:1082-1090.
13. Delmas PD, Balena R, Confravreux E, Hardouin C, Hardy P, Bremond A. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol. 1997;15:955-962.
14. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled parallel-group study. Arthritis Rheum. 1999;42: 2309-2318.
15. Mortensen L, Charles P, Bekker PJ, Digennaro J, Johnston CC Jr. Risedronate increases bone mass in an early post-menopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab. 1998;83:396-402.
16. Green JR, Müller K, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res. 1994;9:745-751.
17. Bare S, Kimmel D, Binkley N, Schaffer V, Green J. Zoledronate (CGP 42,446) suppresses turnover without affecting mineralization in cancellous bone of the ovariectomized non-human primate [abstract S482]. J Bone Miner Res. 1997; 12(Suppl 1):S473.
18. Binkley N, Kimmel D, Brunner J, et al. Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys. J Bone Miner Res. 1998;13: 1775-1782.
19. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a Phase III, double-blind, comparative trial. Cancer J. 2001;7:377-387.
20. Lipton A, Small E, Saad F, et al. The new bisphosphonate, Zometa (Zoledronic Acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest. 2002;20(Suppl):45-47.
21. Jagdev SP, Purohito P, Heatley S, Herling C, Coleman RE. Comparison of the effect of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol. 2001;12:1433-1438.
22. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309-319.
23. Clohisy DR, Rammaraine ML, Scully S, et al. Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice [abstract]. Presented at the Second North American Symposium on Skeletal Complications of Malignancy, Montreal, Quebec, Canada. October 15-16, 1999.
24. Morony S, Capparelli C, Kostenuik PJ, et al. Osteoprotegerin prevents bone destruction in athymic and syngeneic models of experimental tumor metastasis to bone [abstract]. Presented at the Second North American Symposium on Skeletal Complications of Malignancy, Montreal, Quebec, Canada. October 15-16, 1999.
25. Body JJ, Greipp P, Coleman RE, et al. Osteoprotegerin and bone metastases [abstract]. Presented at the Third North American Symposium on Skeletal Complications of Malignancy, Bethesda, MD, April 25-27, 2002.
26. Powell GJ, Southby J, Danks JA, et al. Localization of parathyroid hormone-related protein in breast cancer metastasis: increased incidence in bone compared with other sites. Cancer Res. 1991;51:3059-3061.
27. Guise TA, Yin JJ, Taylor SD, et al. Evidence for a causal role of parathyroid hormone-related protein in breast cancer-mediated osteolysis. J Clin Invest. 1996;98:1544-1548.
28. Guise TA. Molecular mechanism of osteolytic bone metastases. Cancer. 2000;88(12 Suppl):2892-2897.
29. Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol. 1997;13:513-609.
30. Biscardi JS, Tice DA, Parson SJ. c-Src, receptor tyrosine kinases, and human cancer. Adv Cancer Res. 1999;76:61-119.
31. Susa M, Missbach M, Green J. Src inhibitors: drugs for the treatment of osteoporosis, cancer or both? Trends Pharmacol Sci. 2000;21:489-495.
32. Susa M, Teti A. Tyrosine kinase Src inhibitors: potential therapeutic applications. Drug News Perspect. 2000;13:169-175.
33. c-Src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest. 1992; 90:1622-1627.
34. c-Src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest. 1992; 90:1622-1627.
35. Missbach M, Jeschke M, Feyer J, et al. A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Bone. 1999;24:437-449.
36. Kneissel M, Gamse R, Missbach M, et al. Tyrosine kinase Src inhibitor CGP 76030 suppresses rapid bone loss induced by retinoic acid in rats. Calcif Tissue Int. 1999; 64(Suppl 1):S75.